Treatment | Benefit | Reference |
Radiotherapy plus concomitant and adjuvant temozolomide for versus radiotherapy alone for newly diagnosed glioblastoma | Two-year survival rate was 26.5 percent with radiotherapy plus temozolomide and 10.4 percent with radiotherapy only group | [7] |
Addition of bevacizumab to radiotherapy and temozolomide for newly diagnosed glioblastoma | Longer progression-free survival (10.6 months vs. 6.2 months) with the addition of bevacizumab | [73] |
Bevacizumab and lomustine for treating first recurrences | Progression-free survival was 4.17 months with combination treatment vs. 1.54 months of those receiving only lomustine | [74] |
Cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma | Cediranib produced a modest decreased time to deterioration in neurologic status, corticosteroid-sparing effects | [75] |